NameEmoxipin. Release form Solution. INNMethylethylpyridinol. FTGA Antioxidant agent. CompositionActive ingredients: Emoxipin (Methyl ethy lpyridinol hydrochloride) 150 mg Excipients: 1 M sodium hydroxide solution to pH 4.8 – 5.8, Water for injection up to 5 ml. Pharmacological actionEmoxipin has a beneficial effect on the blood coagulation system: it inhibits platelet aggregation, reduces the overall coagulation index, and prolongs the blood clotting time. Enhances the process of fibrinolysis. Reduces blood viscosity, vascular wall permeability. Stabilizes the membranes of blood vessel cells and erythrocytes, increases the resistance of erythrocytes to mechanical injury and hemolysis. It has angioprotective properties. Improves microcirculation. Effectively inhibits free-radical lipid oxidation of biomembranes, increases the activity of antioxidant enzymes. Stabilizes cytochrome P-450, has an antitoxic effect. In extreme situations, accompanied by an increase in lipid peroxidation and hypoxia, it optimizes bioenergetic processes. Emoksipin reduces signs of cerebral hemodysfunction. Increases the resistance of the brain to hypoxia and ischemia. In case of disorders of cerebral circulation (ischemic and hemorrhagic), it contributes to the correction of autonomic dysfunctions, facilitates the restoration of the integrative activity of the brain, and improves mnestic functions. Expands the coronary vessels, reduces the ischemic clinical course of myocardial infarction, reducing the incidence of heart failure. It contributes to the regulation of the redox system in case of circulatory insufficiency. Pharmacokinetics When administered intravenously at a dose of 10 mg / kg, the half-life of Ti / g is 18 minutes; total clearance CI – 0.2 l / min; the apparent volume of distribution Vd is 5.2 liters. The drug quickly penetrates into organs and tissues, where it is deposited and metabolized. Five emoxipine metabolites were found, represented by dealkylated and conjugated products of its transformation. Emoxypine metabolites are excreted by the kidneys. Significant amounts of 2-ethyl-6-methyl-3-oxypyridine-phosphate are found in the liver. Under pathological conditions, for example, in the case of coronary occlusion, the pharmacokinetics of emoxipine changes. The rate of excretion decreases, the residence time of emoxipin in the bloodstream increases, which may be due to its return from the depot, including from the ischemic myocardium. Indications for use In neurology and neurosurgery in complex therapy: hemorrhagic stroke, ischemic stroke in the basin of the internal carotid artery and in the vertebrobasilar system, transient cerebrovascular accidents, chronic cerebrovascular insufficiency, craniocerebral injury, accompanied by brain contusions; postoperative period in patients with traumatic brain injury operated on for epi-, subdural and intracerebral hematomas, combined with brain contusions; pre- and postoperative period in patients with arterial aneurysms and arteriovenous malformations of cerebral vessels. In cardiology in complex therapy: acute myocardial infarction, prevention of “reperfusion syndrome”, unstable angina pectoris. ContraindicationsIncreased individual sensitivity to medicinal lactation period, children under 18 years of age. Method of administration and doses Doses, duration of treatment are determined individually. In neurology and neurosurgery, emoxipin is used intravenously in a daily dose of 5-10 mg/kg for 10-12 days. Before administration, emoxipine is diluted in 200 ml of isotonic sodium chloride solution. Enter at a rate of 20 – 30 drops per minute. Subsequently, they switch to intramuscular injection of 2-10 ml of a solution of 30 mg / ml of emoxipine (60-300 mg) 2-3 times a day for 10-30 days. In cardiology, they begin with an intravenous drip (20-40 drops per minute) injection of 20-30 ml of a solution of 30 mg / ml of emoxipine (600-900 mg) in 200 ml of isotonic sodium chloride solution 1-3 times a day for 5-15 days depending on the course of the disease, followed by the transition to intramuscular injection of 2-10 ml of a solution of 30 mg / ml of emoxipine (60-300 mg) 2-3 times a day for 10-30 days. Treatment with emoxipin, in the case of its intravenous and intramuscular administration, should be carried out under the control of blood pressure and the functional state of the blood coagulation and anticoagulation systems. Side effect Excitation, drowsiness, increased blood pressure, reaction at the injection site (burning sensation along the vein, pain, itching). In rare cases, headache, pain in the heart area are possible, in persons with chronic pathology of the digestive system – nausea, discomfort in the epigastric region. With a predisposition to allergic reactions, in rare cases, itching and redness of the skin are observed. Overdose In case of overdose, the side effects of the drug may increase. Symptoms: increased blood pressure, agitation or drowsiness, headache, pain in the heart, nausea, discomfort in the epigastric region. There may be a bleeding disorder. Treatment: symptomatic therapy, there is no specific antidote. Interaction with other drugs Negative manifestations in the use of emoxipine against the background of therapy with other drugs are not described. a – Tocopherol acetate potentiates the antioxidant effect of emoxipin. Emoxipin is not recommended to be mixed with other injectables in the same syringe. Precautions It is necessary to constantly monitor blood pressure and blood clotting during treatment. Pregnancy and lactation Use during pregnancy is contraindicated. It is possible to use the drug during lactation (breastfeeding) according to indications, if the expected effect of therapy outweighs the potential risk to the fetus. Effects on the ability to drive vehicles and potentially dangerous mechanisms The drug does not affect the ability to drive vehicles and machinery. Release form: 5 ml vials. 10 bottles together with instructions for use are placed in a cardboard box. Storage conditions Store in a place protected from light at a temperature not exceeding 25 ° C. Keep out of the reach of children. Shelf life 2 years. Do not use after the expiration date. Terms of dispensing from pharmacies By prescription. Buy Emoksipin eye drops 10mg/ml 5ml №1
Emoxipin eye drops 10mg/ml 5ml №1
$8.00
SKU: 19501
Category: Medicines for diseases of the eyes and ears
INN | METHYLETHYLPYRIDINOL |
---|---|
The code | 19 501 |
Barcode | 4 810 133 007 229 |
Dosage | 10mg/ml 5ml |
Active substance | Emoxipin |
Manufacturer | Belmedpreparaty RUE, Belarus |
Be the first to review “Emoxipin eye drops 10mg/ml 5ml №1” Cancel reply
Related products
Medicines for diseases of the eyes and ears
Dexatobrom eye drops in a dropper bottle (1mg+3mg)/1ml 5ml №1
$20.00
Medicines for diseases of the eyes and ears
Dexamethasone eye drops 1mg/ml 5ml complete with dropper cap #1
$14.00
Medicines for diseases of the eyes and ears
$8.00
Medicines for diseases of the eyes and ears
$14.00
Reviews
There are no reviews yet.